- 21,010 women diagnosed with ovarian cancer in the U.S. in 2026
- 12,450 deaths expected from ovarian cancer in the U.S. in 2026
- 600+ ANGEL Advocates trained by Tigerlily in breast cancer by 2024
Experts would likely conclude that corporate-nonprofit alliances like Genmab and Tigerlily Foundation are strategically essential to bridge gaps in patient education, particularly for underserved communities, while also driving commercial success for targeted therapies.
Corporate-Nonprofit Alliances: Genmab Fuels Tigerlily's Ovarian Expansion
WASHINGTON, D.C. – November 19, 2026 – The path from a promising therapeutic prototype to a profitable, market-leading drug is rarely a straight line. Often, the greatest barriers to commercial success aren't found in the laboratory, but in the clinic—specifically, in the systemic bottlenecks that prevent the right patients from receiving the right treatments at the right time.
Today, Tigerlily Foundation, a national women’s health and oncology nonprofit, announced a major expansion of its programming into ovarian cancer. Backed by biotechnology company Genmab, the initiative aims to deploy self-paced online courses, "ANGEL EMPOWER" chats, and targeted educational toolkits to help women recognize symptoms, understand biomarker testing, and navigate clinical trials.
For two decades, Tigerlily has built a formidable reputation in breast cancer advocacy. Now, the organization is attempting to translate that success to a significantly deadlier, more elusive disease. "In two decades of breast cancer advocacy, I've heard women describe what it's like to keep asking for answers when they know something is wrong," said Maimah Karmo, Founder, President and CEO of Tigerlily Foundation. "We want women facing ovarian cancer to have that same support, from the first time they raise a concern to the decisions they face about testing, treatment, and what comes next."
Bridging the Advocacy Divide
The commercial and clinical infrastructure surrounding breast cancer—standardized mammography, ubiquitous public awareness campaigns, and clear clinical pathways—stands in stark contrast to ovarian cancer.
According to the U.S. Preventive Services Task Force (USPSTF) and the American Cancer Society, routine screening for ovarian cancer in average-risk, asymptomatic women is actively recommended against. The potential for harm from false positives and unnecessary surgeries outweighs the unproven mortality benefits. Consequently, there is no "mammogram equivalent" for ovarian cancer.
Instead, early detection relies almost entirely on symptom literacy—recognizing persistent bloating or pelvic pain—and aggressive self-advocacy. This dynamic creates a treacherous patient journey and a highly fragmented market for therapeutic interventions. By 2024, Tigerlily had trained more than 600 "ANGEL Advocates" in breast cancer, successfully doubling the share of participants who rated their oncology health knowledge as "excellent." Applying this proven peer-navigator model to ovarian cancer represents a strategic effort to manufacture the patient awareness that organic screening protocols cannot provide.
Tackling a Deadly Disparity
The absence of standard screening disproportionately impacts marginalized communities. The American Cancer Society estimates that 21,010 women will be diagnosed with ovarian cancer in the United States in 2026, with an estimated 12,450 dying from the disease. Within these grim statistics lies a stark racial divide.
Tigerlily is explicitly prioritizing outreach to Black women, a demographic that historically faces severe inequities in gynecologic oncology. Peer-reviewed data indicates that Black women are more likely to be diagnosed with advanced-stage epithelial ovarian cancer and are less likely to receive guideline-concordant care, such as optimal surgical debulking and standard chemotherapy regimens.
Crucially, Black patients also face systemic barriers to genetic counseling and biomarker testing. "I wish my mother's ovarian cancer had been caught sooner. Maybe the outcome would have been different. I carry that with me every day," said Lashelle Scott, an ANGEL Advocate and Caregiver. "Education and awareness can make a difference for other families."
When a demographic is systematically under-tested for biomarkers like BRCA mutations, they are effectively locked out of the market for advanced, targeted therapies. Addressing this disparity is not merely a public health imperative; for pharmaceutical developers, it is a critical market access challenge.
The Strategic Calculus of Corporate-Nonprofit Alliances
This is where Genmab’s financial support of the Tigerlily initiative comes into sharp commercial focus. While the exact financial terms of the partnership remain undisclosed, the strategic alignment is undeniable.
Genmab is not a passive philanthropic observer; the company has a massive commercial stake in the ovarian cancer landscape. In late 2022, the FDA granted accelerated approval to Genmab's Elahere (mirvetuximab soravtansine), an antibody-drug conjugate (ADC) targeting folate receptor-alpha (FRα) in platinum-resistant ovarian cancer. This was converted to full approval in early 2024.
Elahere represents a paradigm shift, but its commercial viability depends entirely on patients knowing their biomarker status. If patients, particularly in underserved communities, are not educated about the necessity of biomarker testing, they will never be prescribed FRα-targeted therapies. Furthermore, Genmab is actively running clinical trials to move Elahere into earlier lines of therapy. With the FDA increasingly mandating diversity in clinical trial enrollment, Tigerlily’s grassroots network among Black women provides an invaluable bridge to historically underrepresented patient populations.
By funding Tigerlily’s educational toolkits—which explicitly include materials helping women understand genetic and biomarker testing—Genmab is investing in top-of-funnel market development. A biotech executive familiar with such alliances noted that pharmaceutical companies increasingly view health literacy programs as essential infrastructure. "You can develop the most innovative targeted therapy in the world," the executive observed, "but if the patient doesn't know to ask for the diagnostic test, your drug stays on the shelf. Funding community advocacy is a direct investment in market access."
The ROI of Patient Empowerment
The academic literature consistently validates the clinical return on investment for patient navigation programs. Lay health advocates and peer navigators have been shown to reduce delays in diagnosis, improve adherence to complex treatment regimens, and facilitate access to clinical trials.
In the context of commercialization, an empowered patient is a catalyst. When Tigerlily’s ANGEL Advocates help a patient navigate the labyrinthine healthcare system, they are simultaneously smoothing the friction points that delay therapeutic intervention and revenue generation. The initiative includes #PullUpASeat on-demand webinars and downloadable resources designed to prepare patients for conversations about recurrence and follow-up care—the exact junctures where novel therapeutics are typically introduced.
Tigerlily is currently inviting additional funders and healthcare organizations to scale this community education model. As the organization measures whether women feel better prepared to discuss symptoms and testing with their medical teams, the broader biopharma industry will be watching closely.
The partnership between Genmab and Tigerlily Foundation illustrates a maturing commercialization strategy in modern oncology. It acknowledges that the journey from prototype to profit requires more than just FDA approval; it requires an educated, empowered patient population capable of demanding the innovations the industry produces. By aligning corporate resources with grassroots advocacy, companies can simultaneously advance health equity and secure the commercial foundation of their most promising therapeutics.
Topics & Related
Partnership
Health Equity
Oncology
📝 This article is still being updated
Are you a relevant expert who could contribute your opinion or insights to this article? We'd love to hear from you. We will give you full credit for your contribution.
Contribute Your Expertise →